Market Size of Global Diabetic Retinopathy Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
Forecast Data Period | 2024 - 2029 |
CAGR | 11.50 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Diabetic Retinopathy Market Analysis
The Diabetic Retinopathy Market is poised to grow at a CAGR of 11.5% during the study period, 2022-2027.
The COVID-19 pandemic led to disruption in not only the research and development activities of other therapies and drugs for medical conditions other than COVID-19 but also impacted the treatment procedures and supply chain of the pharmaceuticals and medical devices around the world which also impacted the studied market of diabetic retinopathy. However, lockdown led to the sudden transition to online activities which not only involved work but also education and entertainment and this led to increase in the screen time of individuals along with usage of vision correction devices such as contact lenses and spectacles. Further, the COVID-19 pandemic is expected to have a long-term impact on the people as today also a significant number of daily activities are being performed online which may have a negative impact on the eyes and led to increase in the demand for vision correction drugs and devices, thus positively impacting the market.
Certain factors that are driving the market growth include the rising prevalence of diabetes and blindness due to the same, growing geriatric population base, increasing technological advancements in diabetic retinopathy surgical instruments.
Diabetic retinopathy (DR) is a leading cause of vision-loss globally. The most clinically important risk factors for progression to vision loss include the duration of diabetes, hyperglycemia, and hypertension. Control of serum glucose and blood pressure have been shown to be effective in preventing vision loss due to DR. There is an increasing burden of diabetic retinopathy across the globe. The increasing burden of diabetes is also driving the growth of market. As per "Diabetic retinopathy screening: a short guide" published by World health Organization in 2020, the prevalence of any retinopathy in persons with diabetes is 35% while proliferative (vision-threatening) retinopathy is 7%. Additionally, the International Diabetes Federation Diabetes Atlas, 10th edition 2021 reported that in 2021, globally there are about 536,600,000 people with diabetes, and it is estimated to reach 783,700,000 by the year 2045. such growing burden of diabetes rises the risk of diabetes retinopathy and thus, expected to drive the growth of market.
Additionally, the services launched for the diagnosis and improvement in diagnosis is also driving the growth of market in the country. For Instance, in December 2021, Eyenuk, Inc in collaboration with Discovery Health has launched a new Diabetic Retinopathy Screening Benefit nationwide in South Africa, powered by the cutting-edge EyeArt Artificial Intelligent System. It helps in enabling the detection of the onset of diabetic retinopathy as early as possible. Such benefits plans and services increases the early detection of the diseases and hence drives the growth of market.
According to the research study published in May 2021, titled 'A deep learning system for detecting diabetic retinopathy across the disease spectrum', the screening of retina can help in the early detection of the diabetic retinopathy which can be used for administering the timely treatment, and as per the study, the DeepDR system achieved high sensitivity and specificity in diabetic retinopathy grading and with the introduction of the image quality sub-network and lesion-aware sub-network into DeepDR, it improved the diagnostic performance and more closely followed the thought process of ophthalmologists. Thus, the DeepDR has great potential to improve the accessibility and efficiency of diabetic retinopathy screening which may be incorporated in the future devices and drive the growth in the studied market.
Hence, the rising prevalence of diabetic retinopathy, along with the growing awareness and concern over it, are expected to drive the market growth over the forecast period. however, lack of skilled ophthalmologists and extended time for product approvals are expected to hinder the market.
Diabetic Retinopathy Industry Segmentation
As per the scope of the report, diabetic retinopathy refers to a diabetes complication that affects eyes, DR results in damage to the blood vessels of the light-sensitive tissue at the back of the eye (retina). Initially, diabetic retinopathy may cause no symptoms or only mild vision problems. But eventually, it can cause blindness. The Diabetic Retinopathy Market is segmented by Type (Proliferative diabetic retinopathy, Non-proliferative retinopathy), Management Approach (Anti-VEGF Drug, Intraocular Steroid Injection, Laser Surgery, and Vitrectomy) and Geography (North America, Europe, Asia - Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
By Type | |
Proliferative Diabetic Retinopathy | |
Non-proliferative Retinopathy |
By Management Approach | |
Anti-VEGF Drug | |
Intraocular Steroid Injection | |
Laser Surgery | |
Vitrectomy |
Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Global Diabetic Retinopathy Market Size Summary
The diabetic retinopathy market is experiencing significant growth, driven by the increasing prevalence of diabetes and the associated risk of vision loss. The market is characterized by advancements in diagnostic and therapeutic technologies, which are enhancing early detection and treatment options. The COVID-19 pandemic has had a dual impact, disrupting supply chains and treatment procedures while also increasing screen time and the use of vision correction devices, thereby boosting demand for diabetic retinopathy solutions. The market is further supported by a growing geriatric population and technological innovations in surgical instruments. However, challenges such as a shortage of skilled ophthalmologists and lengthy product approval processes may hinder market expansion.
North America is expected to be a key region for market growth, fueled by a rising number of diabetes cases and advancements in medical technology. The region's focus on early detection and treatment, supported by initiatives like the integration of artificial intelligence in diagnostic systems, is likely to drive market dynamics. The competitive landscape is moderately concentrated, with major players engaging in strategic partnerships, product launches, and research activities to enhance their market presence. Regulatory approvals and clinical trials continue to play a crucial role in the development and adoption of new treatments, further propelling market growth during the forecast period.
Global Diabetic Retinopathy Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Rising Prevalence of Diabetes and Blindness Due to The Same
-
1.2.2 Growing Geriatric Population Base
-
1.2.3 Increasing Technological Advancements in Diabetic Retinopathy Surgical Instruments
-
-
1.3 Market Restraints
-
1.3.1 Lack of Skilled Ophthalmologists
-
1.3.2 Extended Approval Time for Drugs
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market SIze by Value - in USD Million)
-
2.1 By Type
-
2.1.1 Proliferative Diabetic Retinopathy
-
2.1.2 Non-proliferative Retinopathy
-
-
2.2 By Management Approach
-
2.2.1 Anti-VEGF Drug
-
2.2.2 Intraocular Steroid Injection
-
2.2.3 Laser Surgery
-
2.2.4 Vitrectomy
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle-East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle-East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Global Diabetic Retinopathy Market Size FAQs
What is the current Global Diabetic Retinopathy Market size?
The Global Diabetic Retinopathy Market is projected to register a CAGR of 11.5% during the forecast period (2024-2029)
Who are the key players in Global Diabetic Retinopathy Market?
Regeneron Pharmaceuticals, Inc., Alimera Sciences, Oxurion NV., Abbvie Inc. and F. Hoffmann-La Roche Ltd are the major companies operating in the Global Diabetic Retinopathy Market.